Literature DB >> 17934986

Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients.

Misbah Khurram1, Lone Skov, Kristian Rossen, Henrik S Thomsen, Peter Marckmann.   

Abstract

Nephrogenic systemic fibrosis (NSF) is a fibrotic disease seen in renal failure patients that may lead to severe physical disability. It has been demonstrated in recent studies that NSF can be caused by some gadolinium-containing MRI contrast agents. In this report we present one of a total of 26 cases of gadodiamide-related NSF from our hospital.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934986     DOI: 10.1080/00365590701701327

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  3 in total

Review 1.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

2.  Brain relaxometry after macrocyclic Gd-based contrast agent.

Authors:  Andreas Müller; Alina Jurcoane; Burkhard Mädler; Philip Ditter; Hans Schild; Elke Hattingen
Journal:  Clin Neuroradiol       Date:  2017-07-24       Impact factor: 3.649

3.  Comparison of 1.0 M gadobutrol and 0.5 M gadopentate dimeglumine-enhanced MRI in 471 patients with known or suspected renal lesions: results of a multicenter, single-blind, interindividual, randomized clinical phase III trial.

Authors:  Bernd Tombach; Klaus Bohndorf; Wolfgang Brodtrager; Claus D Claussen; Christoph Düber; Michael Galanski; Eckhardt Grabbe; Giacomo Gortenuti; Michael Kuhn; Walter Gross-Fengels; Renate Hammerstingl; Brigitte Happel; Gertraud Heinz-Peer; Gregor Jung; Thomas Kittner; Roberto Lagalla; Philipp Lengsfeld; Reinhard Loose; Raymond H G Oyen; Pietro Pavlica; Christiane Pering; Roberto Pozzi-Mucelli; Thorsten Persigehl; Peter Reimer; Nomdo S Renken; Götz M Richter; Ernst J Rummeny; Fritz Schäfer; Malgorzata Szczerbo-Trojanowska; Andrzej Urbanik; Thomas J Vogl; Paul Hajek
Journal:  Eur Radiol       Date:  2008-07-08       Impact factor: 5.315

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.